AXL and melanoma: We therefore propose that identifying expression levels of MITF/SOX10, AXL/EGFR/ERBB3 prior to initiation of treatment may contribute to predicting treatment response to MAPK inhibitors and perhaps advice on drug combination strategies in melanoma.